<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02558153</url>
  </required_header>
  <id_info>
    <org_study_id>NL44059.058.13</org_study_id>
    <nct_id>NCT02558153</nct_id>
  </id_info>
  <brief_title>RCT of Paclitaxel DEB Compared to Standard PTA in Dialysis Fistula</brief_title>
  <acronym>APERTO</acronym>
  <official_title>A Randomized Trial of Aperto Paclitaxel Eluting Dilatation Catheter Compared to POBA in Dialysis Fistula</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groene Hart Ziekenhuis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Archer Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Groene Hart Ziekenhuis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter randomized clinical trial of paclitaxel drug-eluting balloon (DEB) versus
      standard percutaneous transluminal angioplasty (PTA) to reduce restenosis in 150 patients
      with haemodialysis access stenoses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective multicenter randomized (1:1) Investigator Sponsored Trial, in which 150
      consecutive patients candidates for percutaneous intervention of haemodialysis access will be
      randomly assigned to one of two study arms:

        1. Treatment Arm: paclitaxel drug-eluting balloon (DEB) dilatation using the APERTO-balloon

        2. Control Arm: standard percutaneous transluminal angioplasty (PTA).

      The aim is to evaluate the safety and efficacy of paclitaxel drug-eluting balloon (DEB) for
      the reduction of restenosis in haemodialysis shunts compared to standard percutaneous
      transluminal angioplasty (PTA).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adequate functioning of the hemodialysis access</measure>
    <time_frame>6 months</time_frame>
    <description>Period of adequate functioning of the hemodialysis access after treatment, defined according to the NKF-DOQI protocol criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>device success</measure>
    <time_frame>index procedure (day 0)</time_frame>
    <description>ability of the DEB to be delivered, inflated at pressure ≤ RBP, and retrieved from the Target Lesion without burst</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical Success</measure>
    <time_frame>index procedure (day 0)</time_frame>
    <description>achievement of a lumen diameter of at least 70% of the nominal diameter of either the DEB or the post dilatation PTA balloon (whichever is bigger) by visual estimate and without bail-out stenting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Success</measure>
    <time_frame>6 months</time_frame>
    <description>improvement in haemodialysis access failure and resumption of normal dialysis for at least one dialysis session after the index procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>Index procedure (day 0)</time_frame>
    <description>Technical Success without the occurrence of MAE (MAE defined here as: death, stroke, thrombotic occlusion, allergic reaction, pulmonary events (including pulmonary edema)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAE - major adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>MAE defined as: death or stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>thrombotic occlusion of target lesion</measure>
    <time_frame>6 months</time_frame>
    <description>thrombotic occlusion of target lesion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>thrombotic occlusion of target hemodialysis access</measure>
    <time_frame>6 months</time_frame>
    <description>thrombotic occlusion of target hemodialysis access</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically driven Target Lesion Revascularization (TLR)</measure>
    <time_frame>6 months</time_frame>
    <description>Clinically driven Target Lesion Revascularization (TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically driven Target Shunt Revascularization (TSR)</measure>
    <time_frame>6 months</time_frame>
    <description>Clinically driven Target Shunt Revascularization (TSR)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Complication of Hemodialysis</condition>
  <condition>Vascular Access Complication</condition>
  <arm_group>
    <arm_group_label>DEB - drug eluting balloon (APERTO)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Percutaneous balloon angioplasty performed with the investigational device, the paclitaxel eluting APERTO balloon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard PTA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Percutaneous balloon angioplasty performed with the clinical standard, that is, a non-drug-eluting balloon (POBA, plain old balloon angioplasty).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DEB, drug eluting balloon</intervention_name>
    <description>Percutaneous angioplasty performed with a DEB - drug eluting balloon</description>
    <arm_group_label>DEB - drug eluting balloon (APERTO)</arm_group_label>
    <other_name>Paclitaxel eluting balloon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>standard PTA</intervention_name>
    <description>Percutaneous angioplasty performed with a standard balloon</description>
    <arm_group_label>standard PTA</arm_group_label>
    <other_name>POBA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All criteria 1-10 must apply for inclusion.

          1. Age &gt; 18 years and &lt; 90 years

          2. Patient or legally authorized representative providing written informed consent

          3. Patient willing and likely to comply with the follow up schedule

          4. Patients with previously well functioning hemodialysis access on the arm presenting
             with any of the following clinical abnormalities as defined in the NKF-DOQI-protocol
             criteria (National Kidney Foundation 2000):

               -  Abnormal physical examination findings (change in bruits, thrill, pulse, etc

               -  Abnormal urea recirculation measurements

               -  Elevated venous pressure during dialysis

               -  Decreased access flow

               -  Previous thrombosis in the access line

               -  Development of collateral veins

               -  Limb swelling

               -  Low arterial pressure during dialysis

               -  Unexplained decreases in dialysis dose

          5. Target Lesion is hemodynamically relevant and consists of MLD ≤ 3 mm. For enrolment
             this criterium is judged by the local investigator. For final analysis this criterium
             is based on the result of central reading of the angiogram.

          6. Target Lesion(s) is a de-novo or (non-stent) restenosis

          7. Target lesion(s) in dialysis fistulas is located at the anastomosis or in the outflow
             venous trajectory up to the level (but excluding) the subclavian vein

          8. Target lesion(s) in dialysis grafts is located at the arterial or venous anastomosis,
             inside the graft, or in the outflow venous trajectory up to the level (but excluding)
             the subclavian vein

          9. Multiple Target Lesions are allowed per patient which can be treated by a number of
             APERTO DEB with aggregate max length of 160 mm

         10. NON Target Lesions (i.e. in the subclavian vein) must be successfully treated with
             standard PTA prior to the Target Lesion.

        Exclusion Criteria:

        None of criteria 1-12 must apply for inclusion.

          1. Patients unable to give informed consent

          2. Patients enrolled in another study with any investigational drug or device

          3. Patients previously enrolled in the APERTO trial.

          4. Female patients of child bearing potential without a negative pregnancy test at the
             time of intervention

          5. Major surgical procedures within 30 days prior to this study or planned within 30 days
             of entry into this study

          6. Patients previously treated with a DEB in the hemodialysis access.

          7. Patients with a trombosed hemodialysis access.

          8. Immature hemodialysis access (unusable due to insufficient shunt flow volume)

          9. Lesion treated within 30 days prior to screening

         10. Failure to successfully treat non-target lesions prior the Target Lesion

         11. In stent restenosis

         12. Patients with any known allergy, hypersensitivity or intolerance to ASA, clopidogrel
             or ticlopidine, paclitaxel, or contrast medium.

         13. Graft infection

         14. Life expectancy &lt; 1 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter MT Pattynama, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groene Hart Ziekenhuis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ina Kool</last_name>
    <phone>+31 182 505196</phone>
    <email>Ina.Kool@ghz.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Annemiek van Mazijk</last_name>
    <phone>+31 182 757224</phone>
    <email>Annemiek.van.Mazijk@ghz.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Geert G Maleux, MD, PhD</last_name>
      <phone>+32 16 332211</phone>
      <email>geert.maleux@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Geert G Maleux, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ZNA Stuivenberg</name>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter P Goverde, MD</last_name>
      <phone>+32 3 2177481</phone>
      <email>peter.goverde@zna.be</email>
    </contact>
    <investigator>
      <last_name>Peter P Goverde, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MC Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <state>Friesland</state>
        <zip>8934 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan JA Dol, MD</last_name>
      <phone>+31 58 2866666</phone>
      <email>j.dol@znb.nl</email>
    </contact>
    <investigator>
      <last_name>Johan JA Dol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atrium Medisch Centrum. Department of radiology</name>
      <address>
        <city>Heerlen</city>
        <state>Limburg</state>
        <zip>6419 PC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roel JJ Heijboer, MD</last_name>
      <phone>+31 45 576666</phone>
      <email>r.heijboer@atriummc.nl</email>
    </contact>
    <contact_backup>
      <phone>+ 31 45 576666</phone>
    </contact_backup>
    <investigator>
      <last_name>Roel JJ Heijboer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Catharina ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <state>Noord-Brabant</state>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xander AV Tielbeek, MD</last_name>
      <phone>'+31 40 2398565</phone>
      <email>xander.tielbeek@catherinaziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>Xander AV Tielbeek, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Lucas Andreas Hospital</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1061 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aloys FJ Wüst, MD</last_name>
      <phone>+31 20 5108911</phone>
      <email>a.wust@slaz.nl</email>
    </contact>
    <investigator>
      <last_name>Aloys FJ Wüst, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groene Hart Ziekenhuis</name>
      <address>
        <city>Gouda</city>
        <state>ZH</state>
        <zip>2803 HH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter MT Pattynama, MD, PhD</last_name>
      <phone>+31 182 505050</phone>
      <email>Peter.Pattynama@ghz.nl</email>
    </contact>
    <contact_backup>
      <last_name>Ina Kool</last_name>
      <phone>+31 182 505196</phone>
      <email>Ina.Kool@ghz.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Peter MT Pattynama, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MC Haaglanden</name>
      <address>
        <city>Den Haag</city>
        <state>Zuid Holland</state>
        <zip>2512 VA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edwin E. Linden, van der, MD</last_name>
      <phone>+31 70 3302000</phone>
      <email>e.van.der.linden@mchaaglanden.nl</email>
    </contact>
    <investigator>
      <last_name>Edwin E. Linden, van der, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <zip>3015CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adriaan A. Moelker, MD</last_name>
      <phone>+31 10 4635987</phone>
      <email>a.moelker@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>Adriaan A. Moelker, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMC Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Job J Oldenziel, MD</last_name>
      <phone>+ 31 50 3614260</phone>
      <email>j.oldenziel@umcg.nl</email>
    </contact>
    <investigator>
      <last_name>Job J Oldenziel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2015</study_first_submitted>
  <study_first_submitted_qc>September 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2015</study_first_posted>
  <last_update_submitted>September 28, 2017</last_update_submitted>
  <last_update_submitted_qc>September 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Groene Hart Ziekenhuis</investigator_affiliation>
    <investigator_full_name>Dr Peter M.T. Pattynama</investigator_full_name>
    <investigator_title>MD, PhD. Interventional radiologist</investigator_title>
  </responsible_party>
  <keyword>drug eluting balloon</keyword>
  <keyword>percutaneous balloon angioplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

